Description
Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. It has potential antineoplastic, anti-inflammatory, and antiangiogenic activities. It inhibits other kinases including vascular endothelial growth factor receptor (VEGFR2) and Src tyrosine kinases